Correlation between pregnanesteroid conformation, receptor affinity, and anti-natriuretic effect

European Journal of Pharmacology

Volumn 454, Issue 2-3, 2002, Pages 131-143

  Piwien Pilipuk, Graciela ^a   Kanelakis, Kimon C ^b   Galigniana, Mario D ^a,b  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Aldosterone; Mineralocorticoid receptor; Natriuresis; Steroid conformation

Indexed keywords

11BETA,17BETA DIHYDROXY 6 METHYL 17ALPHA (1 PROPYNYL)ANDROSTA 1,4,6 TRIEN 3 ONE; FUNCTIONAL GROUP; LIGAND; MINERALOCORTICOID RECEPTOR; PREGNANE DERIVATIVE; PREGNANESTEROID; SODIUM ION; STEROID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIDIURESIS; ARTICLE; BINDING AFFINITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG CONFORMATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SODIUM RETENTION; ANIMAL; CELL STRAIN COS1; CERCOPITHECUS; CHEMISTRY; DOSE RESPONSE; DRUG EFFECT; HUMAN; METABOLISM; NATRIURESIS; PHYSIOLOGY; PROTEIN BINDING; RAT; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION;

ANIMALS; CERCOPITHECUS AETHIOPS; COS CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MALE; NATRIURESIS; PREGNANES; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MINERALOCORTICOID; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0037111505     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02492-5     Document Type: Article

References (31)

1. Agarwal M.K., Mirshahi M. General overview of mineralocorticoid action. Pharmacol. Ther. 84:2000;273-326.
2. Alnemri E.S., Maksymowych A.B., Robertson N.M., Litwack G. Overexpression and characterization of the human mineralocorticoid receptor. J. Biol. Chem. 266:1991;18072-18081.
3. Bastl C.P., Hayslett J.P. The cellular action of aldosterone in target epithelia. Kidney Int. 42:1992;250-264.
4. Brachet-Cota A.L., Burton G. An improved preparation of 11,19-oxidopregn-4-ene-3,20-dione and 6,19-oxidopregn-4-ene-3,11,20-trione. Z. Naturforsch. T.b. 45:1990;711-715.
5. Burton G., Galigniana M.D., deLavallaz S., Brachet-Cota A.L., Sproviero E.M., Ghini A.A., Lantos C.P. Sodium-retaining activity of some natural and synthetic 21-deoxysteroids. Mol. Pharmacol. 47:1995;535-543.
6. Chen H., Lin R.J., Xie W., Wilpitz D., Evans R.M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell. 98:1999;675-686.
7. Dluhy R.G. Glucocorticoid-remediable aldosteronism. Endocrinologist. 11:2001;263-268.
8. Fagart J., Wurtz J.M., Souque A., Hellal-Levy C., Moras D., Rafestin-Oblin M.E. Antagonism in the human mineralocorticoid receptor. EMBO J. 17:1998;3317-3325.
9. Farman N., Rafestin-Oblin M.E. Multiple aspects of mineralocorticoid selectivity. Am. J. Physiol. Renal Physiol. 280:2001;F181-F192.
10. Funder J.W. Aldosterone action: fact, failure and the future. Clin. Exp. Pharmacol. Physiol. 25:1998;S47-S50.
11. Funder J.W. Aldosterone and mineralocorticoid receptors: orphan questions. Kidney Int. 57:2000;1358-1363.
12. Funder J.W., Pearce P., Smith R., Smith A.I. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 242:1988;583-585.
13. Galigniana M.D. Native rat kidney mineralocorticoid receptor is a phosphoprotein whose transformation to a DNA-binding form is induced by phosphatases. Biochem. J. 333:1998;555-563.
14. Galigniana M.D. Functional regulation of corticosteroid receptors by phosphorylation and redox potential. Curr. Top. Steroid Res. 3:2000;1-22.
15. Galigniana M.D., Piwien-Pilipuk G. Comparative inhibition by hard and soft metal ions on steroid-binding capacity of renal mineralocorticoid receptor cross-linked to the 90-kDa heat-shock protein heterocomplex. Biochem. J. 341:1999;585-592.
16. Galigniana M.D., Vicent G.P., Lantos C.P., Burton G. Ligand properties of 11,19-oxidoprogesterone: a preliminary report. An. Asoc. Quím. Argent. 81:1993;333-340.
17. Galigniana M.D., Vicent G.P., Burton G., Lantos C.P. Features of the shuttle pair 11β-hydroxyprogesterone/11-ketoprogesterone. Steroids. 62:1997;358-364.
18. Galigniana M.D., Vicent G.P., Piwien-Pilipuk G., Burton G., Lantos C.P. Mechanism of action of the potent sodium-retaining steroid 11,19-oxidoprogesterone. Mol. Pharmacol. 58:2000;58-70.
19. Grassy G., Fagart J., Calas B., Adenot M., Rafestin-Oblin M.E., Auzou G. Structure-activity relationships of steroids with mineralocorticoid activity. Eur. J. Med. Chem. 32:1997;869-879.
20. Koshida H., Miyamori I., Soma R., Matsubara T., Ikeda M., Takeda R., Nakamura S., Kiuchi F., Tsuda Y. Mineralocorticoid and renal receptor binding activity of 21-deoxyaldosterone. Endocrinology. 126:1990;1410-1415.
21. Lantos C.P., Burton G., Roldán A., Damasco M.C., Aragonés A. Structure-activity relationship in certain glucocorticoids and mineralocorticoids. Soto R.J., de Nicola A., Blaquier J. Physiopathology of Endocrine Diseases and Mechanisms of Hormone Action. 1981;477-494 Alan R. Liss, New York.
22. Lombès M., Kenouch S., Souque A., Farman N., Rafestin-Oblin M.E. The mineralocorticoid receptor discriminates aldosterone from glucocorticoids independently of the 11β-hydroxysteroid dehydrogenase. Endocrinology. 135:1994;834-840.
23. Piwien-Pilipuk G., Galigniana M.D. Tautomycin inhibits phosphatase-dependent transformation of the rat kidney mineralocorticoid receptor. Mol. Cell. Endocrinol. 144:1998;119-130.
24. Piwien-Pilipuk G., Kanelakis K.C., Ghini A.A., Lantos C.P., Litwack G., Burton G., Galigniana M.D. Modification of an essential amino group in the mineralocorticoid receptor evidences a differential conformational change of the receptor protein upon binding of antagonists, natural agonists and the synthetic agonist 11,19-oxidoprogesterone. Biochim. Biophys. Acta. 1589:2001;31-48.
25. Robertson N.M., Schulman G., Karnik S., Alnemri E., Litwack G. Demonstration of nuclear translocation of the mineralocorticoid receptor (MR) using anti-MR antibody and confocal scanning microscopy. Mol. Endocrinol. 7:1993;1226-1239.
26. Sheppard K.E., Funder J.W. Type I receptors in parotid, colon and pituitary are aldosterone-selective in vivo. Am. J. Physiol. 253:1987;E467-E471.
27. Souque A., Fagart J., Coutte B., Davioud E., Marquet A., Rafestin-Oblin M.E. The mineralocorticoid activity of progesterone derivatives depends on the nature of the C18 substituent. Endocrinology. 136:1995;5651-5658.
28. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev. 12:1998;599-606.
29. Teutsch G., Nique F., Lemoine G., Bouchoux F., Cérède E., Gofflo D., Philibert D. General structure-activity correlations of antihormones. Ann. N.Y. Acad. Sci. 761:1995;5-28.
30. Veleiro A.S., Nevado M.V., Monteserín M.C., Burton G. Syntheses of 21-hydroxy-11,19-oxidopregn-4-ene-3,20-dione and 21-hydroxy-6,19-oxidopregn-4-ene-3,20-dione. Steroids. 60:1995;358-364.
31. Young D.B. Quantitative analysis of aldosterone's role in potassium regulation. Am. J. Physiol. 255:1988;F811-F822.